Small Molecule Inhibitor of Type Three Secretion Suppresses Acute and Chronic Chlamydia trachomatis Infection in a Novel Urogenital Chlamydia Model

Previously, we reported that a compound from a group of thiohydrazides of oxamic acids, CL-55, possessed antichlamydial activity in vitro that was accompanied by a decreased translocation of the type three secretion effector, IncA, into the host cell. In this study, the antichlamydial activity of CL...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2015-01, Vol.2015 (2015), p.1-7
Main Authors: Shabalina, Ludmila A., Luyksaar, Sergei I., Zayakin, Egor S., Kobets, Natalia V., Koroleva, Ekaterina A., Zigangirova, Naylia A.
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacology
Chemotherapy
Chlamydia
Chlamydia Infections - drug therapy
Chlamydia trachomatis
Chlamydia trachomatis - drug effects
Deoxyribonucleic acid
DNA
Female
Health aspects
Host-bacteria relationships
Infections
Infertility
Mice
Mice, Inbred DBA
Observations
Organisms
Pathology
Real time
Sexually transmitted diseases
Small Molecule Libraries - pharmacology
STD
Studies
Vagina - microbiology
Women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previously, we reported that a compound from a group of thiohydrazides of oxamic acids, CL-55, possessed antichlamydial activity in vitro that was accompanied by a decreased translocation of the type three secretion effector, IncA, into the host cell. In this study, the antichlamydial activity of CL-55 was tested in vivo in DBA/2 mice infected with C. trachomatis serovar D. We found that intravaginal inoculation of DBA/2 mice with the clinically relevant strain, C. trachomatis serovar D, results in a course of infection and pathology similar to that observed in humans. The early stage of infection in this model was characterized by a shedding of Chlamydia in vaginal secretions followed by an ascending infection and inflammation in the upper genital tract. We found that CL-55 possessed antibacterial activity in vivo and was able to control C. trachomatis vaginal shedding, ascending infection, and inflammation in the upper genital organs in DBA/2 mice. Our data provide a proof of concept for the protective effect of the thiadiazinon, CL-55, against chlamydial infection in vivo and support the feasibility of further studies of its potential therapeutic applications.
ISSN:2314-6133
2314-6141
DOI:10.1155/2015/484853